uCD7 chimeric antigen receptor T cells

uCD7 chimeric antigen receptor T cells represent an advanced form of immunotherapy, specifically a cell and gene therapy, designed to combat CD7-positive malignancies and potentially autoimmune diseases. This therapy involves genetically engineering a patient's or a healthy donor's T cells to express a chimeric antigen receptor (CAR) that precisely targets the CD7 protein, a cell surface marker prevalent on malignant T cells in conditions like T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) and certain acute myeloid leukemia (AML) cases, as well as on normal T and NK cells. A critical challenge in developing CD7-targeting CAR T cells is preventing "fratricide," where the engineered T cells attack each other due to their own CD7 expression. This is overcome through genetic modifications, such as CRISPR/Cas9 or base editing, to knock out CD7 expression in the CAR T cells, rendering them fratricide-resistant. These modified T cells are then expanded ex vivo and infused into the patient, where they recognize and eliminate CD7-expressing cancer cells through T-cell mediated cytotoxicity. The goal is to provide an "off-the-shelf" allogeneic treatment option, reducing manufacturing complexities and improving accessibility.

Other names

CD7 CAR T cellsCD-7 CAR T cellsCD 7 CAR T cellsCD7-targeting CAR T cellsCD-7-targeting CAR T cellsCD 7-targeting CAR T cellsanti-CD7 CAR T cellsanti-CD-7 CAR T cellsanti-CD 7 CAR T cells